Synergy of gatifloxacin with cefoperazone and cefoperazone–sulbactam against resistant strains of Pseudomonas aeruginosa

References

1. Bajaksouzian, S., Visalli, M. A., Jacobs, M. R. & Appelbaum, P. C. ( 1996; ). Antipneumococcal activities of cefpirome and cefotaxime, alone and in combination with vancomycin and teicoplanin, determined by checkerboard and time–kill methods. Antimicrob Agents Chemother 40, 1973–1976.
   [Google Scholar]
2. Dawis, M. A., Isenberg, H. D., France, K. A. & Jenkins, S. G. ( 2003; ). In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms. J Antimicrob Chemother 51, 1203–1211.[CrossRef]
   [Google Scholar]
3. Eliopoulos, G. M. & Moellering, R. C., Jr ( 1991; ). Laboratory methods used to assess the activity of antimicrobial combinations. In Antibiotics in Laboratory Medicine, 3rd edn, pp. 432–492. Edited by V. Lorian. Baltimore, MD: Williams & Wilkins.
4. Fish, D. N., Choi, M. K. & Jung, R. ( 2002; ). Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs. J Antimicrob Chemother 50, 1045–1049.[CrossRef]
   [Google Scholar]
5. Gradelski, E., Valera, L., Bonner, D. & Fung-Tomc, J. ( 2001; ). Synergistic activities of gatifloxacin in combination with other antimicrobial agents against Pseudomonas aeruginosa and related species. Antimicrob Agents Chemother 45, 3220–3222.[CrossRef]
   [Google Scholar]
6. Mayer, I. & Nagy, E. ( 1999; ). Investigation of the synergic effects of aminoglycoside-fluoroquinolone and third-generation cephalosporin combinations against clinical isolates of Pseudomonas spp. J Antimicrob Chemother 43, 651–657.[CrossRef]
   [Google Scholar]
7. CLSI ( 1999; ). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 5th edn, approved standard M7–A5. Wayne, PA: Clinical and Laboratory Standards Institute.
8. CLSI ( 2000; ). Performance Standards for Antimicrobial Disk Susceptibility Test, approved standard M7–A5. Wayne, PA: Clinical and Laboratory Standards Institute.
9. Neu, H. C. & Chin, N. X. ( 1994; ). In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob Agents Chemother 38, 2615–2622.[CrossRef]
   [Google Scholar]
10. Pankey, G. A. & Ashcraft, D. S. ( 2005; ). In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 49, 2959–2964.[CrossRef]
    [Google Scholar]
11. PDR ( 2004; ). Physicians' Desk Reference, 58th edn. Montvale, NJ: Thomsons.
12. Rossolini, G. M. & Mantengoli, E. ( 2005; ). Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect 11 (Suppl. 4), 17–32.
    [Google Scholar]
13. Visalli, M. A., Jacobs, M. R. & Appelbaum, P. C. ( 1998; ). Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time–kill methodology. Antimicrob Agents Chemother 42, 953–955.
    [Google Scholar]